The third largest drug maker in American, Merck and Co, have released figures showing that their revenue has increased due to wider usage of the diabetes pill Januvia . Further revenue earned outside America helped the drug company post good results.
The news is fortunate for Merck, because a study into their cholesterol drug Vytorin could raise controversy. The SEAS study may strongly affect sales. One American analyst, Tim Anderson of Sandford C. Bernstei, reportedly commented: “SEAS will likely have some negative impact on prescribing trends, but we would have said this whether the cancer finding was there or not..”
Sales of diabetic drug Januvia and Janumet doubled to $406 million, and it is thought that controversy surrounding diabetes drug Avandia could have aided these sales. Avandia was the subject of a journal report that strongly linked it to heart problems and death.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…